Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.54 |
| ▸ | AGXT | P21549 | 2/20 | 0.54 |
| ▸ | MAOB | P27338 | 8/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5571216 | 0.85 | USP2 (0.46) | IDO1AGXTMAOBAPP | |
| SCHEMBL7888039 | 0.85 | IDO1 (0.64) | IDO1AGXTMAOBAPPLOXL2 | |
| SCHEMBL5981060 | 0.82 | IDO1 (0.50) | IDO1AGXTMAOBAPPLOXL2 | |
| SCHEMBL5979665 | 0.79 | IDO1 (0.47) | IDO1AGXTMAOBAPP | |
| SCHEMBL22304854 | 0.78 | IDO1 (0.56) | IDO1AGXTMAOBAPPLOXL2 | |
| Hydroxyamine SCHEMBL8923579 | 0.78 | IDO1 (0.62) | IDO1AGXTMAOBAPPLOXL2 | |
| SCHEMBL5978162 | 0.77 | TAAR1 (0.46) | IDO1AGXTMAOBLOXL2TAAR1 | |
| SCHEMBL4343354 | 0.76 | TSHR (0.71) | IDO1AGXTTSHR | |
| SCHEMBL3149166 | 0.76 | IDO1 (0.54) | IDO1AGXTMAOB | |
| SCHEMBL1287166 | 0.76 | IDO1 (0.54) | IDO1AGXTMAOBAPPLOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2200440-A1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | Crestone, Inc. (US) | 2010-06-30 | — | — | EP | claimed |
| WO-2009015208-A1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | REPLIDYNE, INC. (US) | 2009-01-29 | — | — | WO | claimed |
| US-20070191395-A1 | Heterocyclic compounds having antifungal activity | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-08-16 | — | — | US | claimed |
| WO-2007069986-A1 | NEW OXABISPIDINE COMPOUNDS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | WO | claimed |
| EP-1717238-A1 | FUNGICIDAL HETEROCYCLIC COMPOUNDS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-11-02 | — | — | EP | claimed |
| WO-2020021969-A1 | COMPOSITION, CURED PRODUCT, OPTICAL FILTER, AND PRODUCTION METHOD FOR CURED PRODUCT | 株式会社ADEKA | 2020-01-30 | — | — | WO | disclosed |
| EP-2200440-A1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | Crestone, Inc. (US) | 2010-06-30 | — | — | EP | disclosed |
| US-20100081693-A1 | THIADIAZOLE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-04-01 | — | — | US | disclosed |
| EP-2061789-A2 | THIADIAZOLE COMPOUND AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2009-05-27 | — | — | EP | disclosed |
| WO-2009015208-A1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | REPLIDYNE, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
| WO-2008032858-A2 | THIADIAZOLE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008012546-A2 | AZAPEPTIDES FOR USE IN THERAPY AGAINST INTERSTITIAL CYSTITIS | SOSEI CO. LTD. (JP) | 2008-01-31 | — | — | WO | disclosed |
| EP-1717238-A1 | FUNGICIDAL HETEROCYCLIC COMPOUNDS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-11-02 | — | — | EP | disclosed |
| US-7015345-B2 | Propionic acid derivatives | ASAHI KASEI PHARMA CORPORATION (JP) | 2006-03-21 | — | — | US | disclosed |
| EP-1484316-A1 | NOVEL PROPIONIC ACID DERIVATIVE | Asahi Kasei Pharma Corporation (JP) | 2004-12-08 | — | — | EP | disclosed |
| US-20040072690-A1 | Novel propionic acid derivatives | ASAHI KASEI PHARMA CORPORATION (JP) | 2004-04-15 | — | — | US | disclosed |
| EP-0672678-B1 | Azapeptide derivative | FUJIREBIO KK (JP) | 2000-10-25 | — | — | EP | disclosed |
| US-5965538-A | FOR TREATING NERVOUS INFLAMMATION OF RESPIRATORY SYSTEMS, ASTHMA, BRONCHOSPASM | FUJIREBIO INC. (JP) | 1999-10-12 | — | — | US | disclosed |
| US-5837687-A | BRONCHODILATORS, ANTIHISTAMINES AND ANTIINFLAMMATORY AGENTS; ASTHMA; ANTAGONIST OF NEUROKININ RECEPTORS | FUJIREBIO INC. (JP) | 1998-11-17 | — | — | US | disclosed |
| EP-0672678-A1 | Azapeptide derivative | FUJIREBIO Inc. (JP) | 1995-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072690-A1 | Novel propionic acid derivatives | PNLIP, LIPC, GPR119 | IDO1 4434/4885AGXT 186/4885MAOB 3357/4885 |
| US-20070191395-A1 | Heterocyclic compounds having antifungal activity | ERG28, MANBA, MAN2B1 | IDO1 609/4885AGXT 81/4885MAOB 1769/4885 |
| US-20100081693-A1 | THIADIAZOLE COMPOUND AND USE THEREOF | NR2C2, NR4A3, NR0B2 | IDO1 1716/4885AGXT 3155/4885MAOB 1907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.